Abivax Shares Drop Despite Positive Ulcerative Colitis Drug Trial Results
Despite positive Phase 3 maintenance trial results for its ulcerative colitis drug obefazimod, Abivax (ABVX) shares fell by 32% in premarket trading. The drop was attributed to concerns over the drug's potential cancer-related side effects overshadowing its efficacy.
Tickers: $ABVX
Topics: gastrointestinal drugs pharmaceuticals stock market reaction